Add to ORKGInterferon (IFN) beta has been an effective treatment for relapsing–remitting multiple sclerosis (RRMS) for many years. However, some currently available IFN beta ther-apies require injection several times a week because the
This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta1a ...
Damiano Paolicelli, Vita Direnzo, Maria TrojanoDepartment of Neurological and Psychiatric Sciences, ...
Proposed beta-interferon (IFN beta) treatment failure criteria for patients with relapsing-remitting...
Since its approval in the USA in 1993, interferon beta (IFNb) has been widely used to reduce relapse...
Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive ...
The first pharmacon with proved efficacy for the treatment of patients with the relapsing-remitting ...
Intramuscular interferon beta-1a therapy provides a means of reducing the accumulation of physical d...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...
Randomized clinical trials (RCTs) have provided evidence for the efficacy of interferon beta (IFNbet...
Patients with multiple sclerosis have a lifelong disease for which no cure is currently available. T...
Several treatments are currently available for relapsing-remitting multiple sclerosis. Among them, i...
Betaseron (IFN-1b) is approved for treatment of relapsing remitting multiple sclerosis (MS). The age...
Angela Applebee, Hillel PanitchDepartment of Neurology, University of Vermont College of Medicine, a...
Interferon beta preparations are the most widely used initial therapies prescribed for patients with...
Background: The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting mu...
This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta1a ...
Damiano Paolicelli, Vita Direnzo, Maria TrojanoDepartment of Neurological and Psychiatric Sciences, ...
Proposed beta-interferon (IFN beta) treatment failure criteria for patients with relapsing-remitting...
Since its approval in the USA in 1993, interferon beta (IFNb) has been widely used to reduce relapse...
Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive ...
The first pharmacon with proved efficacy for the treatment of patients with the relapsing-remitting ...
Intramuscular interferon beta-1a therapy provides a means of reducing the accumulation of physical d...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...
Randomized clinical trials (RCTs) have provided evidence for the efficacy of interferon beta (IFNbet...
Patients with multiple sclerosis have a lifelong disease for which no cure is currently available. T...
Several treatments are currently available for relapsing-remitting multiple sclerosis. Among them, i...
Betaseron (IFN-1b) is approved for treatment of relapsing remitting multiple sclerosis (MS). The age...
Angela Applebee, Hillel PanitchDepartment of Neurology, University of Vermont College of Medicine, a...
Interferon beta preparations are the most widely used initial therapies prescribed for patients with...
Background: The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting mu...
This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta1a ...
Damiano Paolicelli, Vita Direnzo, Maria TrojanoDepartment of Neurological and Psychiatric Sciences, ...
Proposed beta-interferon (IFN beta) treatment failure criteria for patients with relapsing-remitting...